Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
MRC Population Health Research Unit, Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
BMJ Qual Saf. 2024 Oct 18;33(11):716-725. doi: 10.1136/bmjqs-2023-016520.
Antiplatelet therapy (APT) can substantially reduce the risk of further vascular events in individuals with established atherosclerotic cardiovascular disease (ASCVD). However, knowledge regarding the extent and determinants of APT use is limited.
Estimate the extent and identify patient groups at risk of suboptimal APT use at different stages of the treatment pathway.
Retrospective cohort study using linked NHS Scotland administrative data of all adults hospitalised for an acute ASCVD event (n=150 728) from 2009 to 2017. Proportions of patients initiating, adhering to, discontinuing and re-initiating APT were calculated overall and separately for myocardial infarction (MI), ischaemic stroke and peripheral arterial disease (PAD). Multivariable logistic regression and Cox proportional hazards models were used to assess the contribution of patient characteristics in initiating and discontinuing APT.
Of patients hospitalised with ASCVD, 84% initiated APT: 94% following an MI, 83% following an ischaemic stroke and 68% following a PAD event. Characteristics associated with lower odds of initiation included female sex (22% less likely than men), age below 50 years or above 70 years (aged <50 years 26% less likely, and aged 70-79, 80-89 and ≥90 years 21%, 39% and 51% less likely, respectively, than those aged 60-69 years) and history of mental health-related hospitalisation (45% less likely). Of all APT-treated individuals, 22% discontinued treatment. Characteristics associated with discontinuation were similar to those related to non-initiation.
APT use remains suboptimal for the secondary prevention of ASCVD, particularly among women and older patients, and following ischaemic stroke and PAD hospitalisations.
抗血小板治疗(APT)可显著降低已确诊的动脉粥样硬化性心血管疾病(ASCVD)患者进一步发生血管事件的风险。然而,目前对 APT 使用的程度和决定因素知之甚少。
评估在 ASCVD 治疗路径的不同阶段,APT 使用不足的程度和识别高危患者群体。
这是一项使用苏格兰国民保健署(NHS Scotland)行政数据进行的回顾性队列研究,纳入了 2009 年至 2017 年期间因急性 ASCVD 事件住院的所有成年人(n=150728)。计算了患者总体起始、坚持、中断和重新起始 APT 的比例,分别针对心肌梗死(MI)、缺血性卒中和外周动脉疾病(PAD)进行计算。使用多变量逻辑回归和 Cox 比例风险模型评估患者特征对起始和中断 APT 的影响。
在因 ASCVD 住院的患者中,84%的患者起始了 APT:94%的 MI 患者、83%的缺血性卒中和 68%的 PAD 患者。起始 APT 的可能性较低的特征包括女性(比男性低 22%)、年龄小于 50 岁或大于 70 岁(年龄<50 岁的可能性低 26%,年龄 70-79 岁、80-89 岁和≥90 岁的可能性分别低 21%、39%和 51%,与年龄 60-69 岁相比)和有心理健康相关住院史(低 45%)。在所有接受 APT 治疗的患者中,有 22%的患者中断了治疗。与起始治疗相关的特征与未起始治疗的特征相似。
APT 在 ASCVD 的二级预防中仍未得到充分利用,特别是在女性和老年患者中,以及在缺血性卒中和 PAD 住院患者中。